Treatment of post-treatment Lyme disease symptoms-a systematic review.
Lyme disease
Lyme neuroborreliosis
fatigue
post‐treatment Lyme disease syndrome
systematic review
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
revised:
01
03
2024
received:
17
01
2024
accepted:
19
03
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
Residual symptoms after treatment of Lyme disease, sometimes called post-treatment Lyme disease symptoms (PTLDs), are a matter of ongoing controversy. To guide treatment recommendations, a systematic review was performed of the available literature on specific treatment for PTLDs. A systematic literature search of MEDLINE and CENTRAL was performed. No restrictions on case definitions, study types or specific interventions were applied to enable a comprehensive overview of the available literature. Risk of bias was assessed using the Cochrane risk of bias tools for randomized controlled trials. Certainty of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. Outcomes of interest were quality of life, fatigue, depression and cognition as well as adverse events. After screening 1274 records, eight eligible randomized controlled trials were included. Heterogeneity was observed regarding inclusion criteria, intervention, length of treatment and outcome measures. For efficacy outcomes, results are presented narratively due to heterogeneity. Eligible studies show no statistically significant difference between antibiotics and placebo regarding quality of life, cognition and depression. Results for fatigue were inconsistent whilst studies with low risk of bias showed no statistically significant difference between antibiotics and placebo. Meta-analysis of safety outcomes showed statistically significantly more adverse events for antibiotics compared to placebo. Available literature on treatment of PTLDs is heterogeneous, but overall shows evidence of no effect of antibiotics regarding quality of life, depression, cognition and fatigue whilst showing more adverse events. Patients with suspected PTLDs should not be treated with antibiotics.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Residual symptoms after treatment of Lyme disease, sometimes called post-treatment Lyme disease symptoms (PTLDs), are a matter of ongoing controversy. To guide treatment recommendations, a systematic review was performed of the available literature on specific treatment for PTLDs.
METHODS
METHODS
A systematic literature search of MEDLINE and CENTRAL was performed. No restrictions on case definitions, study types or specific interventions were applied to enable a comprehensive overview of the available literature. Risk of bias was assessed using the Cochrane risk of bias tools for randomized controlled trials. Certainty of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. Outcomes of interest were quality of life, fatigue, depression and cognition as well as adverse events.
RESULTS
RESULTS
After screening 1274 records, eight eligible randomized controlled trials were included. Heterogeneity was observed regarding inclusion criteria, intervention, length of treatment and outcome measures. For efficacy outcomes, results are presented narratively due to heterogeneity. Eligible studies show no statistically significant difference between antibiotics and placebo regarding quality of life, cognition and depression. Results for fatigue were inconsistent whilst studies with low risk of bias showed no statistically significant difference between antibiotics and placebo. Meta-analysis of safety outcomes showed statistically significantly more adverse events for antibiotics compared to placebo.
CONCLUSIONS
CONCLUSIONS
Available literature on treatment of PTLDs is heterogeneous, but overall shows evidence of no effect of antibiotics regarding quality of life, depression, cognition and fatigue whilst showing more adverse events. Patients with suspected PTLDs should not be treated with antibiotics.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16293Subventions
Organisme : German Neurological Society
Informations de copyright
© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Dersch R, Sommer H, Rauer S, Meerpohl JJ. Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol. 2016;263(1):17‐24.
Wormser GP, Weitzner E, McKenna D, et al. Long‐term assessment of health‐related quality of life in patients with culture‐confirmed early Lyme disease. Clin Infect Dis. 2015;61(2):244‐247.
Asch ES, Bujak DI, Weiss M, Peterson MG, Weinstein A. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol. 1994;21(3):454‐461.
Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089‐1134.
Marques A. Persistent symptoms after treatment of Lyme disease. Infect Dis Clin N Am. 2022;36(3):621‐638.
Turk SP, Lumbard K, Liepshutz K, et al. Post‐treatment Lyme disease symptoms score: developing a new tool for research. PLoS One. 2019;14(11):e0225012.
Ursinus J, Vrijmoeth HD, Harms MG, et al. Prevalence of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study. Lancet Reg Health Eur. 2021;6:100142.
Vrijmoeth HD, Ursinus J, Harms MG, et al. Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study. EBioMedicine. 2023;13:104825.
Hernández SA, Ogrinc K, Korva M, et al. Association of persistent symptoms after Lyme neuroborreliosis and increased levels of interferon‐α in blood. Emerg Infect Dis. 2023;29(6):1091‐1101.
Gyllemark P, Sjöwall J, Forsberg P, Ernerudh J, Henningsson AJ. Intrathecal Th17‐driven inflammation is associated with prolonged post‐treatment convalescence for patients with Lyme neuroborreliosis. Sci Rep. 2023;13(1):9722.
Wormser GP, Weitzner E, McKenna D, Nadelman RB, Scavarda C, Nowakowski J. Long‐term assessment of fatigue in patients with culture‐confirmed Lyme disease. Am J Med. 2015;128(2):181‐184.
Kalish RA, Kaplan RF, Taylor E, Jones‐Woodward L, Workman K, Steere AC. Evaluation of study patients with Lyme disease, 10–20‐year follow‐up. J Infect Dis. 2001;183(3):453‐460.
Dersch R, Sarnes AA, Maul M, et al. Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol. 2015;262(11):2572‐2577.
Andreassen S, Solheim AM, Ljøstad U, et al. Cognitive function in patients with neuroborreliosis: a prospective cohort study from the acute phase to 12 months post treatment. Brain Behav. 2022;12(6):e2608.
Halperin JJ, Eikeland R, Branda JA, Dersch R. Lyme neuroborreliosis: known knowns, known unknowns. Brain. 2022;145:2635‐2647.
Teodoro T, Chen J, Gelauff J, Edwards MJ. Functional neurological disorder in people with long COVID: a systematic review. Eur J Neurol. 2023;30(5):1505‐1514.
Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti‐Infect Ther. 2014;12(9):1103‐1135.
Frankl S, Hadar PN, Yakhkind A, Lang AE, Sandsmark DK. Devastating neurological injury as a result of treatment of ‘chronic Lyme disease’. Mayo Clin Proc. 2021 Jul;96(7):2005‐2007.
Goodlet KJ, Fairman KA. Adverse events associated with antibiotics and intravenous therapies for post‐Lyme disease syndrome in a commercially insured sample. Clin Infect Dis. 2018;67(10):1568‐1574.
Marzec NS, Nelson C, Waldron PR, et al. Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease—United States. MMWR Morb Mortal Wkly Rep. 2017;66(23):607‐609.
Dersch R, Freitag MH, Schmidt S, et al. Efficacy and safety of pharmacological treatments for neuroborreliosis—protocol for a systematic review. Syst Rev. 2014;21(3):117.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928.
Dersch R, Freitag MH, Schmidt S, Sommer H, Rauer S, Meerpohl JJ. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis—a systematic review. Eur J Neurol. 2015;22(9):1249‐1259.
Dersch R, Rauer S. Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis: an updated systematic review. Eur J Neurol. 2023;30(12):3780‐3788.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002;21(11):1539‐1558.
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401‐406.
Berende A, ter Hofstede HJM, Vos FJ, et al. Randomized trial of longer‐term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374(13):1209‐1220.
Murray L, Alexander C, Bennett C, Kuvaldina M, Khalsa G, Fallon B. Kundalini yoga for post‐treatment Lyme disease: a preliminary randomized study. Healthcare. 2022;10(7):1314.
Cameron D. Severity of Lyme disease with persistent symptoms. Insights from a double‐blind placebo‐controlled clinical trial. Minerva Med. 2008;99(5):489‐496.
Sjöwall J, Ledel A, Ernerudh J, Ekerfelt C, Forsberg P. Doxycycline‐mediated effects on persistent symptoms and systemic cytokine responses post‐neuroborreliosis: a randomized, prospective, cross‐over study. BMC Infect Dis. 2012;10(12):186.
Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo‐controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992‐1003.
Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(2):85‐92.
Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP‐LD): a randomized double masked clinical trial. Neurology. 2003;60(12):1923‐1930.
Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post‐treatment Lyme disease: do additional antibiotics help? Neurology. 2003;60(12):1916‐1922.
Knudtzen FC, Eikeland R, Bremell D, et al. Lyme neuroborreliosis with encephalitis; a systematic literature review and a Scandinavian cohort study. Clin Microbiol Infect. 2022;28(5):649‐656.
Klempner MS, Baker PJ, Shapiro ED, et al. Treatment trials for post‐Lyme disease symptoms revisited. Am J Med. 2013;126(8):665‐669.
Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Neurology. 2021;96(6):262‐273.
Jaulhac B, Saunier A, Caumes E, et al. Lyme borreliosis and other tick‐borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis. Med Mal Infect. 2019;49(5):335‐346.
Nemeth J, Bernasconi E, Heininger U, For The Swiss Society For Infectious Diseases And The Swiss Society For Neurology, et al. Update of the Swiss guidelines on post‐treatment Lyme disease syndrome. Swiss Med Wkly. 2016;146:w14353.
Zhang X, Jiang Y, Chen Y, et al. Efficacy and safety of antibiotic therapy for post‐Lyme disease? A systematic review and network meta‐analysis. BMC Infect Dis. 2023;23(1):22.
Chaimani A, Caldwell D, Li T, Higgins J, Salanti G. Chapter 11: Undertaking network meta‐analyses. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions Version 64. Cochrane; 2023. www.training.cochrane.org/handbook.
Raffetin A, Chahour A, Schemoul J, et al. Acceptance of diagnosis and management satisfaction of patients with ‘suspected Lyme borreliosis’ after 12 months in a multidisciplinary reference center: a prospective cohort study. BMC Infect Dis. 2023;23(1):380.
De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33(3):e00181‐19.